51
|
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart Disease and Stroke Statistics—2010 Update. Circulation 2010; 121:e46-e215. [PMID: 20019324 DOI: 10.1161/circulationaha.109.192667] [Citation(s) in RCA: 2604] [Impact Index Per Article: 186.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
52
|
Du Y, Scheidt-Nave C, Schaffrath Rosario A, Ellert U, Dören M, Knopf H. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study. Climacteric 2010; 12:329-40. [PMID: 19437194 DOI: 10.1080/13697130902745120] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND There are virtually no prospective cohort studies in Germany regarding the changes of menopausal hormone therapy (HT) use pattern and factors associated with HT discontinuation after the release of the Women's Health Initiative (WHI) trial results. METHODS We assessed HT prevalence and use pattern as well as factors associated with HT discontinuation in a cohort of 903 women 40 years of age and older, who participated in two consecutive follow-up visits in a 20-year prospective health study from July 2000 to February and from August 2002 to December 2004. RESULTS Overall, the prevalence of HT users in the cohort declined significantly from 35.4% in 2000-2002 to 22.5% in 2002-2004. Adjusting for aging of the population, a statistically significant decrease in HT user prevalence was consistently observed across subgroups of HT users defined by type and duration of HT use. The decline was most pronounced with respect to women using combined estrogen-progestin regimens (-10.5%), higher-dose estrogens (-11.6%), oral preparations (-11.1%), as well as long-term HT users (-8.4%). The prevalence of women indicating HT use for climacteric symptoms decreased significantly (-12.4%), whereas the prevalence of women reporting use of HT for the prevention of osteoporosis increased (+1.8%) significantly. Irrespective of hysterectomy status, half of the women who continued HT changed their HT preparations and switched to lower estrogen doses (11.5%), topical estrogens (8.2%), or phytohormones (3.8%). We did not observe any significant differences between women who continued and discontinued HT regarding health-related characteristics of the study population as of 2000-2002. However, women seeing a gynecologist in the 12 months preceding the 2002-2004 visit were significantly less likely to discontinue HT use in bivariate and multivariate analyses. CONCLUSIONS Substantial declines in HT user prevalence as well as changes in HT use patterns to lower-dose estrogen preparations and non-oral routes of administration are likely to reflect effects of the publication of the WHI results. Consulting a gynecologist appeared to be relevant for a woman's decision to continue HT.
Collapse
Affiliation(s)
- Y Du
- Department of Epidemiology and Health Monitoring, Division of Non-Communicable Disease Epidemiology, Robert Koch Institute, Berlin, Germany
| | | | | | | | | | | |
Collapse
|
53
|
Lorenzi DRSD, Catan LB, Cusin T, Felini R, Bassani F, Arpini AC. Caracterização da qualidade de vida segundo o estado menopausal entre mulheres da Região Sul do Brasil. REVISTA BRASILEIRA DE SAÚDE MATERNO INFANTIL 2009. [DOI: 10.1590/s1519-38292009000400011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJETIVOS: caracterizar a qualidade de vida de mulheres climatéricas residentes na Região Sul segundo o estado menopausal delas. MÉTODOS: foram entrevistadas 236 mulheres com idades entre 40 e 65 anos, durante feira de saúde realizada em cidade do Sul do Brasil, em março de 2005. Na avaliação da qualidade de vida, utilizou-se a versão brasileira do instrumento Menopause Rating Scale. RESULTADOS: das entrevistadas, 133 eram pré-menopáusicas e 103 pós-menopáusicas. As primeiras referiram sintomas climatéricos moderados e severos em 37,6% e 24,0%, respectivamente, enquanto as mulheres pós-menopáusicas, relataram sintomas moderados e severos em 36,9% e 39,4% dos casos, respectivamente. Os escores globais de qualidade de vida não mostraram diferenças entre os grupos estudados (p=0,12), ainda que o grupo pré-menopáusico tenha referido mais sintomas psicológicos (p=0,05) e o pós-menopáusico mais sintomas somato-vegetativos (p<0,01) e urogenitais (p=0,01). CONCLUSÕES: a qualidade de vida não foi influenciada pelo estado menopausal neste estudo. A maior severidade dos sintomas somato-vegetativos no grupo pós-menopáusico provavelmente se deva ao maior hipoestrogenismo nessa fase, favorecendo sintomas vasomotores e atrofia urogenital. A maior severidade dos sintomas psicológicos entre as mulheres pré-menopáusicas pode estar relacionada à maior preocupação acerca da menopausa e suas implicações para saúde.
Collapse
|
54
|
Hsu A, Card A, Lin SX, Mota S, Carrasquillo O, Moran A. Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk. Am J Public Health 2009; 99:2184-7. [PMID: 19833984 DOI: 10.2105/ajph.2009.159889] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
After randomized trials failed to support the use of hormone replacement therapy (HRT) for preventing cardiovascular disease (CVD), HRT use for postmenopausal women declined. Our analysis of 1999-2000 and 2003-2004 National Health and Nutrition Surveys (NHANES) shows that HRT use decreased 19% (from 27.6 to 8.4%; P<.001) among women with CVD versus 3% (from 19.8 to 16.8%; P=.68) among low-risk women, suggesting that most of the drop in HRT use may be among women prescribed HRT as an unproven treatment to prevent CVD.
Collapse
Affiliation(s)
- Angela Hsu
- Columbia Presbyterian Medical Center, New York, NY 10032, USA
| | | | | | | | | | | |
Collapse
|
55
|
Abstract
OBJECTIVE The aim of this study was to identify provider characteristics associated with hormone therapy prescribing. METHODS The study design is cross-sectional. In December 2005, we mailed surveys to providers practicing in two integrated healthcare delivery systems located in the northwestern and northeastern United States; 379 responded (74%) and 249 (49% of total) granted access to their automated data. Data included provider demographics, practice characteristics, and perceptions about hormone therapy. Provider-specific annual hormone therapy prescribing frequency was calculated as days supply of hormone therapy filled divided by the number of visits (among women aged 45-80 y). Factors associated with higher rates of hormone therapy prescribing were identified using bivariate and multivariate analyses. RESULTS We report results separately for primary care providers (internists and family practitioners) and obstetrician/gynecologists because significant correlates differed in these two groups. For both primary care providers and obstetrician/gynecologists, in multivariate analyses, hormone therapy prescribing varied by site (P < or = 0.002) and years at the healthcare organization (P < or = 0.01). For primary care providers only, higher hormone therapy prescribing was associated with reported expert knowledge of the hormone therapy trials (P < or = 0.001). For obstetrician/gynecologists, higher hormone therapy prescription was related to feeling well prepared to counsel women on hormone therapy (P < or = 0.007), believing that the risks of estrogen with progestogen had been exaggerated (P = 0.04), and seeing younger aged patients (P = 0.03). CONCLUSIONS After the release of the Women's Health Initiative findings and practicing under similar clinical guidelines, hormone therapy prescribing is associated with providers' confidence, practice location, and time with a healthcare organization.
Collapse
|
56
|
George J, Hannah S, Lang CC. ThiaZolidineDiones and the Influence of Media Adverse Reporting on Prescribing Attitudes in PraCTice (TZD-IMPACT) Study. Cardiovasc Ther 2009; 27:83-8. [DOI: 10.1111/j.1755-5922.2009.00083.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
57
|
Power ML, Anderson BL, Schulkin J. Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause 2009; 16:500-8. [PMID: 19169162 PMCID: PMC2762611 DOI: 10.1097/gme.0b013e31818fc36e] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To examine the opinions of obstetrician-gynecologists regarding hormone therapy (HT) and the results from the Women's Health Initiative (WHI). METHODS Separate surveys were sent to two groups of practicing obstetrician-gynecologists: (1) respondents to a 2004-2005 survey (follow-up 1) and (2) members of the American College of Obstetricians and Gynecologists' Collaborative Ambulatory Research Network (follow-up 2 CARN). These studies complete a longitudinal study investigating obstetrician-gynecologists' opinions of the evidence from WHI. RESULTS Response rates were 64.5% and 58.8%, respectively. Responses from both surveys were generally consistent with the results from the 2004-2005 survey. A majority of physicians from both survey populations were skeptical of the combined HT results. Respondents were more likely to find the results of the unopposed estrogen trial convincing. Similar to the results from the 2004-2005 study, CARN physicians generally disagreed with the decision to end the WHI trials. Unlike the 2004-2005 study, there was no consistent effect of either age or year that residency was completed on physician opinions. Similar to the 2004-2005 study, physicians who considered alternative therapies as viable treatment options were more likely to report that they found the trial results convincing. The results from follow-up 2 CARN indicate that physicians in the south were most likely and physicians in the east were least likely to prescribe HT, suggesting that unmeasured sociocultural parameters might influence HT prescribing practice. CONCLUSIONS Obstetrician-gynecologists remain generally skeptical of the WHI results, although less so of the estrogen-only trial. The early end to the trials may have contributed to their skepticism.
Collapse
Affiliation(s)
- Michael L Power
- Research Department, American College of Obstetricians and Gynecologists, Washington, DC 20024, USA.
| | | | | |
Collapse
|
58
|
Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 2009; 16:77-83. [PMID: 18703983 DOI: 10.1097/gme.0b013e31817b816e] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE To determine the trend in incidence of fractures among perimenopausal and postmenopausal women during the periods immediately before and after publication of the Women's Health Initiative and Heart and Estrogen/Progestin Replacement Study (HERS) II data. DESIGN This was an ecological study using a claims database for multiple healthcare plans. The cohort of women aged 40 to 69 years was included. Diagnostic codes for fractures likely to be osteoporosis related and prescriptions for hormone therapy and other bone-modifying medications were identified. Annual incidence rates and trends in incidence over time for fractures and prescriptions were determined for the period 2000 through 2005. RESULTS Enrollment among women aged 40 to 69 years increased from 919,389 in 2000 to 2,872,372 in 2005. A total of 43,017 new fractures were identified. There was a significant increasing trend in age-adjusted rates of radius and ulna, vertebra, ribs, hip, pelvis, multiple, and pathologic fractures during the period from 2003 through 2005 (P < 0.03). The incidence of each fracture type was significantly greater during 2004 to 2005 than 2000 to 2001 (P < 0.04). The use of estrogen, estrogen plus progestin, and other hormones declined over the period from 2000 to 2003, whereas the use of other bone-modifying drugs increased from 2003 through 2005. CONCLUSIONS The incidence of fractures among perimenopausal and postmenopausal women increased significantly in the 3 years after publication of Women's Health Initiative and Heart and Estrogen/Progestin Replacement Study II results. This trend followed a decline in the use of hormone therapy, concurrent with an increase in the use of other bone-modifying agents.
Collapse
|
59
|
Media reporting of health interventions: signs of improvement, but major problems persist. PLoS One 2009; 4:e4831. [PMID: 19293924 PMCID: PMC2652829 DOI: 10.1371/journal.pone.0004831] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2008] [Accepted: 02/02/2009] [Indexed: 11/19/2022] Open
Abstract
Background Studies have persistently shown deficiencies in medical reporting by the mainstream media. We have been monitoring the accuracy and comprehensiveness of medical news reporting in Australia since mid 2004. This analysis of more than 1200 stories in the Australian media compares different types of media outlets and examines reporting trends over time. Methods and Findings Between March 2004 and June 2008 1230 news stories were rated on a national medical news monitoring web site, Media Doctor Australia. These covered a variety of health interventions ranging from drugs, diagnostic tests and surgery to dietary and complementary therapies. Each story was independently assessed by two reviewers using ten criteria. Scores were expressed as percentages of total assessable items deemed satisfactory according to a coding guide. Analysis of variance was used to compare mean scores and Fishers exact test to compare proportions. Trends over time were analysed using un-weighted linear regression analysis. Broadsheet newspapers had the highest average satisfactory scores: 58% (95% CI 56–60%), compared with tabloid newspapers and online news outlets, 48% (95% CI 44–52) and 48% (95% CI 46–50) respectively. The lowest scores were assigned to stories broadcast by human interest/current affairs television programmes (average score 33% (95% CI 28–38)). While there was a non- significant increase in average scores for all outlets, a significant improvement was seen in the online news media: a rise of 5.1% (95%CI 1.32, 8.97; P 0.009). Statistically significant improvements were seen in coverage of the potential harms of interventions, the availability of treatment or diagnostic options, and accurate quantification of benefits. Conclusion Although the overall quality of medical reporting in the general media remains poor, this study showed modest improvements in some areas. However, the most striking finding was the continuing very poor coverage of health news by commercial current affairs television programs.
Collapse
|
60
|
Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009; 118:425-32. [DOI: 10.1007/s10549-009-0346-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2009] [Accepted: 02/10/2009] [Indexed: 10/21/2022]
|
61
|
Silverman BG, Kokia ES. Use of hormone replacement therapy, 1998-2007: sustained impact of the Women's Health Initiative findings. Ann Pharmacother 2009; 43:251-8. [PMID: 19193581 DOI: 10.1345/aph.1l438] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Trials of hormone replacement therapy (HRT) for prevention of chronic disease in postmenopausal women have suggested that the risks of treatment outweigh the benefits. The publication in 2002 of the Women's Health Initiative (WHI) study sparked a rapid decline in HRT purchases among American women. OBJECTIVE To examine the impact of the WHI findings on patterns of HRT use in Israeli women. METHODS We linked purchases of estrogen preparations from 1998 to 2007 by female Israeli health maintenance organization members aged 45 years and older to membership data. For each year, we calculated total annual purchases and rate of HRT utilization, characterized new users by age and mode of therapy, and examined rates of switching between modes of therapy. RESULTS Twenty percent of women aged 45 years and older purchased estrogen products in 2001, versus 10% in 2007 (p < 0.001; chi(2)). Vaginally administered products accounted for a rising percentage of purchases, from 5% in 1999 to 18% in 2007. An increasing percentage of new users aged 55 years and older started with a vaginal product (62% in 1999, 82% in 2007). After 2002, new users of oral therapy discontinued use more quickly than those who started oral therapy before 2002. Tibolone accounted for an increasing percentage of oral drugs purchased (12% in 2003, 29% in 2007). CONCLUSIONS The WHI findings had a rapid and sustained impact on HRT utilization in a large population of Israeli women, including a sharp decrease in the rate of use, particularly of oral preparations, as well as reduced duration of therapy and increased use of vaginal preparations and tibolone as first choices for treatment.
Collapse
Affiliation(s)
- Barbara G Silverman
- Department of Research and Evaluation, Maccabi Healthcare Services, Tel Aviv, Israel.
| | | |
Collapse
|
62
|
Abstract
Our objective was to estimate the relationship between longitudinal change in BMD and fragility fractures. We studied 3635 women and 1417 men 50-85 yr of age in the Canadian Multicentre Osteoporosis Study who had at least two BMD measurements (lumbar spine, femoral neck, total hip, and trochanter) within the first 5 yr of the study and fragility fractures (any, main, forearm/wrist, ribs, hip) within the first 7 yr. Multiple logistic regression was used to model the relationship between baseline BMD, BMD change, and fragility fractures. We found that, among nonusers of antiresorptives, independent of baseline BMD, a decrease of 0.01 g/cm(2)/yr in total hip BMD was associated with an increased risk of fragility fracture with ORs of 1.15 (95% CI: 1.01; 1.32) in women and 1.34 (95% CI: 1.02; 1.78) in men. The risk of fragility fractures in subgroups such as fast losers and those with osteopenia was better estimated by models that included BMD change than by models that included baseline BMD but excluded BMD change. Although the association between baseline BMD and fragility fractures was similar in users and nonusers of antiresorptives, the association was stronger in nonusers compared with users. These results show that BMD change in both men and women is an independent risk factor for fragility fractures and also predicts fracture risk in those with osteopenia. The results suggest that BMD change should be included with other variables in a comprehensive fracture prediction model to capture its contribution to osteoporotic fracture risk.
Collapse
|
63
|
Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009; 122:42-52.e2. [PMID: 19114171 DOI: 10.1016/j.amjmed.2008.07.026] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2008] [Revised: 07/23/2008] [Accepted: 07/25/2008] [Indexed: 11/30/2022]
Abstract
PURPOSE To evaluate the health and economic outcomes of hormone therapy in younger and older postmenopausal women. METHODS We developed a cost-effectiveness model to evaluate outcomes associated with hormone therapy in younger and older postmenopausal women, using data sources from published literature through March 2008. The target population was 50-year-old and 65-year-old women given hormone therapy or no therapy, and then followed over their lifetime. Primary outcomes measured were quality-adjusted life-years (QALYs) and incremental cost per QALY gained. RESULTS For the base-case analysis, hormone therapy for 15 years in the younger cohort resulted in a gain of 1.49 QALYs with an incremental cost of $2438 per QALY gained, compared with no therapy. The results for younger women were robust to all sensitivity analyses, and treatment remained highly cost-effective (<$10,000 per QALY gained) within the range of individual assumptions used. Treatment durations of 5 years and 30 years also were highly cost-effective. In the older cohort, treatment for 15 years resulted in a net gain of 0.11 QALYs with a cost of $27,953 per QALY gained. However, a loss of QALYs was seen in the first 9 years. The results for older women were sensitive to many of the assumptions used. CONCLUSIONS Hormone therapy for 5 to 30 years in younger postmenopausal women increases quality-adjusted life-years and is cost-effective. Hormone therapy started in later years results in a loss of quality-adjusted life for several years before a net gain can be realized.
Collapse
Affiliation(s)
- Shelley R Salpeter
- Department of Medicine, Santa Clara Valley Medical Center, San Jose, Calif 95128, USA.
| | | | | | | |
Collapse
|
64
|
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 119:e21-181. [PMID: 19075105 DOI: 10.1161/circulationaha.108.191261] [Citation(s) in RCA: 1356] [Impact Index Per Article: 84.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
65
|
Podmore SH, Botha J, Gray A, Esterhuizen T. Impact of recent evidence on the use of hormone therapy in the South African private sector (2001–2005). S Afr Fam Pract (2004) 2008. [DOI: 10.1080/20786204.2008.10873780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
66
|
Farley JF, Blalock SJ, Cline RR. Effect of the women's health initiative on prescription anti-osteoporosis medication utilization. Osteoporos Int 2008; 19:1603-12. [PMID: 18373048 DOI: 10.1007/s00198-008-0607-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2007] [Accepted: 02/14/2008] [Indexed: 12/26/2022]
Abstract
UNLABELLED Publication of the Women's Health Initiative (WHI) resulted in a 39% reduction in hormone therapy utilization and a 29% increase in the use of new anti-osteoporosis medications. Overall, the prevalence of prescription anti-osteoporosis medication use declined following the WHI. This has important implications for osteoporosis prevention and treatment. INTRODUCTION Women who discontinued hormone therapy (HT) following the Women's Health Initiative (WHI) may have been more likely to initiate treatment with newer anti-osteoporosis medications (AOM). The objective of this study was to examine the influence of the WHI on AOM utilization among a nationally representative sample of older adult women in the U.S. METHODS We used the Medical Expenditure Panel Survey (MEPS) to examine AOM utilization among women aged 50 years and older. National estimates of AOM utilization were predicted from a sample of 2089 women interviewed five times between 2002 and 2003. AOM utilization was dichotomized for HT and newer AOM. Generalized estimating equations were used to predict odds ratios (OR) for AOM utilization controlling for potential predisposing, enabling, and need confounders. RESULTS Prior to the WHI, there were 8.7 and 3.6 million U.S. women using HT and newer AOM, respectively. One year following publication of the WHI, 5.3 million HT users persisted [OR 0.638 (95% CI: 0.617, 0.756)] while 4.7 million women used newer AOM [1.337 (95% CI: 1.120, 1.597)]. CONCLUSIONS Although reductions in HT utilization were accompanied by increased utilization of newer AOM, treatment prevalence for osteoporosis remains sub-optimal.
Collapse
Affiliation(s)
- J F Farley
- Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, CB #7360, 2201 Kerr Hall, Chapel Hill, NC 27599-7360, USA.
| | | | | |
Collapse
|
67
|
Collins NH, Lessey EC, DuSell CD, McDonnell DP, Fowler L, Palomino WA, Illera MJ, Yu X, Mo B, Houwing AM, Lessey BA. Characterization of antiestrogenic activity of the Chinese herb, prunella vulgaris, using in vitro and in vivo (Mouse Xenograft) models. Biol Reprod 2008; 80:375-83. [PMID: 18923163 DOI: 10.1095/biolreprod.107.065375] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Prunella vulgaris (PV), a commonly used Chinese herb, also known as Self-heal, has a wide range of reported medicinal activities. By screening multiple herbs using the endometrial cancer cell line, ECC-1, and an alkaline phosphatase detection assay, we found that PV displayed significant antiestrogenic activity. We investigated the possible usefulness of antiestrogenic activity using both in vitro and in vivo models of endometrial function. Using the well-differentiated, hormone-responsive endometrial cell line, ECC-1, PV extract, at concentrations that were not toxic to the cells, significantly reduced alkaline phosphatase activity and cell proliferation in response to estrogen in a dose-dependent manner. The expression of CYR61, an estrogen-induced protein, was blocked in ECC-1 cells by both the antiestrogen ICI 182,780 and PV extract. Interestingly, PV extract did not appear to directly inhibit estrogen signaling. Rather, we found that its activities were probably related to an ability to function as an aryl hydrocarbon receptor (AHR) agonist in ECC-1 cells. In support of this hypothesis, we noted that PV induced CYP1A1, CYP1B1, and AHR repressor expression in a dose-dependent manner--responses that were blocked by small interfering RNA treatment to reduce AHR and specific AHR antagonists. Ovariectomized immunodeficient RAG-2/gamma(c) knockout mice implanted with human endometrial xenografts developed implants only when treated with estrogen. Mice treated with estrogen and PV tea in their drinking water had fewer and smaller xenograft implants compared with their estrogen-treated counterparts that drank only water (P < 0.05). Analysis of the resulting implants by immunohistochemistry demonstrated persistent estrogen receptor (ER), but reduced proliferation and CYR61 expression. Mouse uterine tissue weight in PV-treated mice was not different from controls, and cycle fecundity of intact C57 female mice was unaffected by PV tea treatment. PV, or Self-heal, exhibits significant antiestrogenic properties, both in vitro and in vivo. This activity is likely due to the ability of PV-activated AHR to interfere with estrogen. This herb may be useful as an adjunct for the treatment of estrogen-dependent processes like endometriosis and breast and uterine cancers. Full characterization of this herb will likely provide new insights into the crosstalk between AHR and ESR1, with potential for therapeutic applications in women.
Collapse
Affiliation(s)
- Nancy H Collins
- Department of Obstetrics and Gynecology, Greenville Hospital System, Greenville, South Carolina 29605, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
68
|
Abstract
OBJECTIVES To describe hormone therapy (HT) initiation after the 2002 publication of the Women's Health Initiative. DESIGN Observational cohort (1999-2003) of women ages 40 to 79 years, five health plans, used HT in July 2002 and subsequently discontinued or never used before August 2002. RESULTS Of discontinuers, 15.8% (3,203 of 20,205) reinitiated HT. Reinitiation was higher among estrogen users (23.8%) versus estrogen with progestin users (11.3%), and lower among those with diabetes (relative risk [RR]=0.68, 95% CI: 0.61-0.76), cardiovascular disease (RR=0.87, 95% CI: 0.83-0.92), and hyperlipidemia (RR=0.83, 95% CI: 0.79-0.88). Only 2.3% (2,072 of 90,261) of never users initiated (August 2002 to December 2003). First-time initiation was associated with cardiovascular disease (RR=1.17, 95% CI: 1.10-1.25) and hyperlipidemia (RR=1.24, 95% CI: 1.17-1.33) and was less common among those with diabetes (RR=0.70, 95% CI: 0.63-0.79). CONCLUSIONS After the Women's Health Initiative, a minority of women reinitiated or became first-time initiators of HT. Women with cardiovascular disease, diabetes, and hyperlipidemia were less likely to reinitiate; women with cardiovascular disease and hyperlipidemia were more likely to be first-time initiators.
Collapse
|
69
|
Pettee KK, Storti KL, Conroy MB, Ainsworth BE. A Lifestyle Approach for Primary Cardiovascular Disease Prevention in Perimenopausal to Early Postmenopausal Women. Am J Lifestyle Med 2008. [DOI: 10.1177/1559827608320132] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Cardiovascular disease (CVD) is the leading cause of death among women in the United States. A large proportion of deaths attributable to CVD occur in asymptomatic women, making early detection and diagnosis difficult. As a result, women tend to be diagnosed at later stages of disease when compared with men. In addition, women have not experienced as great a decline in CVD mortality in recent decades as have men. Therefore, the development of primary CVD prevention strategies to decrease the CVD risk in women has become a major public health priority and creates the need for alternate strategies to be developed to decrease CVD risk in women. The success of a nonpharmacological, lifestyle approach for primary CVD prevention has recently been demonstrated in perimenopausal to early postmenopausal women. Two clinical trials, the Women's Healthy Lifestyle Project (WHLP) and Women On the Move through Activity and Nutrition (WOMAN) study, examined the role of lifestyle to prevent unfavorable CVD risk factor changes that typically occur as a woman transitions through menopause. In both studies, a lifestyle intervention approach, with modest dietary restrictions and increased leisure physical activity, was effective for weight loss and/or weight maintenance and CVD risk factor reduction. More research is needed to determine the long-term benefits of a lifestyle intervention to prevent CVD in women. The existing evidence suggests that the promotion of healthy lifestyle practices by health care providers is a valuable strategy for CVD risk factor reduction in women transitioning through menopause.
Collapse
Affiliation(s)
- Kelley K. Pettee
- Department of Exercise and Wellness, Arizona State University, Mesa
| | | | - Molly B. Conroy
- Department of Medicine University of Pittsburgh, Pittsburgh, Pennsylvania
| | | |
Collapse
|
70
|
Farmer AP, Légaré F, Turcot L, Grimshaw J, Harvey E, McGowan JL, Wolf F. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2008:CD004398. [PMID: 18646106 DOI: 10.1002/14651858.cd004398.pub2] [Citation(s) in RCA: 150] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Printed educational materials (PEMs) are widely used passive dissemination strategies to improve knowledge, awareness, attitudes, skills, professional practice and patient outcomes. Traditionally they are presented in paper formats such as monographs, publication in peer-reviewed journals and clinical guidelines and appear to be the most frequently adopted method for disseminating information. OBJECTIVES To determine the effectiveness of PEMs in improving process outcomes (including the behaviour of healthcare professionals) and patient outcomes. To explore whether the effect of characteristics of PEMs (e.g., source, content, format, mode of delivery, timing/frequency, complexity of targeted behaviour change) can influence process outcomes (including the behaviour of healthcare professionals and patient outcomes). SEARCH STRATEGY The following electronic databases were searched up to July 2006: (a) The EPOC Group Specialised Register (including the database of studies awaiting assessment (see 'Specialised Register'under 'Group Details'); (b) The Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effectiveness; (c) MEDLINE, EMBASE, CINAHL and CAB Health. An updated search of MEDLINE was done in March 2007. SELECTION CRITERIA We included randomised controlled trials (RCTs) , controlled clinical trials (CCT), controlled before and after studies (CBAs) and interrupted time series analyses (ITS) that evaluated the impact of printed educational materials on healthcare professionals' practice and/or patient outcomes. There was no language restriction. Any objective measure of professional performance (sch as number of tests ordered, prescriptions for a particular drug), or patient health outcomes (e.g., blood pressure, number of caesarean sections) were included. DATA COLLECTION AND ANALYSIS Four reviewers undertook data abstraction independently using a modified version of the EPOC data collection checklist. Any disagreement was resolved by discussion among the reviewers and arbitrators. Statistical analysis was based upon consideration of dichotomous process outcomes, continuous process outcomes, patient outcome dichotomous measures and patient outcome continuous measures. We presented the results for all comparisons using a standard method of presentation where possible. We reported separately for each study the median effect size for each type of outcome, and the median of these effect sizes across studies. MAIN RESULTS Twenty-three studies were included for this review. Evidence from this review showed that PEMs appear to have small beneficial effects on professional practice. RCTs comparing PEMs to no intervention observed an absolute risk difference median: +4.3% on categorical process outcomes (e.g., x-ray requests, prescribing and smoking cessation activities) (range -8.0% to +9.6%, 6 studies), and a relative risk difference +13.6% on continuous process outcomes (e.g., medication change, x-rays requests per practice) (range -5.0% to +26.6%, 4 studies). These findings are similar to those reported for the ITS studies, although significantly larger effect sizes were observed (relative risk difference range from 0.07% to 31%). In contrast, the median effect size was -4.3% for patient outcome categorical measures (e.g., screening, return to work, quit smoking) (range -0.4% to -4.6%, 3 studies)). Two studies reported deteriorations in continuous patient outcome data (e.g., depression score, smoking cessation attempts) of -10.0% and -20.5%. One study comparing PEMs with educational workshops observed minimal differences. Two studies comparing PEMs and education outreach did not have statistically significant differences between the groups. It was not possible to explore potential effect modifiers across studies. AUTHORS' CONCLUSIONS The results of this review suggest that when compared to no intervention, PEMs when used alone may have a beneficial effect on process outcomes but not on patient outcomes. Despite this wide of range of effects reported for PEMs, clinical significance of the observed effect sizes is not known. There is insufficient information about how to optimise educational materials. The effectiveness of educational materials compared to other interventions is uncertain.
Collapse
Affiliation(s)
- Anna P Farmer
- Department of Agricultural, Food and Nutritional Science and The Centre for Health Promotion Studies, University of Alberta, 4-10 Agricultural and Forestry Centre, Edmonton, Alberta, Canada, T6H 4J1.
| | | | | | | | | | | | | |
Collapse
|
71
|
Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, Kreiger N, Tenenhouse A, Goltzman D. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ 2008; 178:1660-8. [PMID: 18559803 DOI: 10.1503/cmaj.071416] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Measurement of bone mineral density is the most common method of diagnosing and assessing osteoporosis. We sought to estimate the average rate of change in bone mineral density as a function of age among Canadians aged 25-85, stratified by sex and use of antiresorptive agents. METHODS We examined a longitudinal cohort of 9423 participants. We measured the bone mineral density in the lumbar spine, total hip and femoral neck at baseline in 1995-1997, and at 3-year (participants aged 40-60 years only) and 5-year follow-up visits. We used the measurements to compute individual rates of change. RESULTS Bone loss in all 3 skeletal sites began among women at age 40-44. Bone loss was particularly rapid in the total hip and was greatest among women aged 50-54 who were transitioning from premenopause to postmenopause, with a change from baseline of -6.8% (95% confidence interval [CI] -7.5% to -4.9%) over 5 years. The rate of decline, particularly in the total hip, increased again among women older than 70 years. Bone loss in all 3 skeletal sites began at an earlier age (25-39) among men than among women. The rate of decline of bone density in the total hip was nearly constant among men 35 and older and then increased among men older than 65. Use of antiresorptive agents was associated with attenuated bone loss in both sexes among participants aged 50-79. INTERPRETATION The period of accelerated loss of bone mineral density in the hip bones occurring among women and men older than 65 may be an important contributor to the increased incidence of hip fracture among patients in that age group. The extent of bone loss that we observed in both sexes indicates that, in the absence of additional risk factors or therapy, repeat testing of bone mineral density to diagnose osteoporosis could be delayed to every 5 years.
Collapse
|
72
|
Huot L, Couris CM, Tainturier V, Jaglal S, Colin C, Schott AM. Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 2008; 19:1047-54. [PMID: 18373055 DOI: 10.1007/s00198-008-0587-1] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2007] [Accepted: 09/19/2007] [Indexed: 11/30/2022]
Abstract
UNLABELLED To assess the prescription patterns of anti-osteoporosis medications, three cross-sectional analyses were performed between 2004 and 2006. Women aged 50 and older were identified from the health insurance claims database of the Rhône-Alpes area. HRT prescriptions decreased while bisphosphonates and raloxifene prescriptions increased, respectively, in different age groups. INTRODUCTION The objective of this study was to assess the prescription patterns of hormone replacement therapy (HRT) and anti-osteoporosis medications (AOM) in post-menopausal French women since the WHI and the revision of the French clinical practice guidelines in 2004. METHODS Three cross-sectional analyses were performed between 2004 and 2006. Women aged 50 and older who had at least one claim for a prescription for HRT, bisphosphonates or raloxifene were identified from health insurance claims database of the Rhône-Alpes area. RESULTS A 39% decrease in the number of women who had HRT was observed (67,241 to 41,024). Twenty-one percent and 18% increases were observed, respectively, for bisphosphonates (39,192 to 47,395) and raloxifene (10,263 to 12,060). HRT and raloxifene were mainly prescribed to women aged 55 to 64 (58% and 39%, respectively), bisphosphonates to women aged 65 to 84 (70%). Ninety-eight percent of women had HRT prescribed by a gynaecologist or a general practitioner (GP). Most AOM were prescribed by a GP; 13% of women had AOM prescribed by a rheumatologist. CONCLUSION Prescriptions for HRT in post-menopausal French women have significantly decreased while bisphosphonates and raloxifene prescriptions have increased, respectively, in different age groups but to a lesser extent than the HRT decrease.
Collapse
Affiliation(s)
- L Huot
- Hospices Civils de Lyon, Pole Information Médicale Evaluation Recherche, Unité d'Epidémiologie, Lyon F69003, France
| | | | | | | | | | | |
Collapse
|
73
|
Krieger N. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol 2008; 37:627-37. [PMID: 18375445 DOI: 10.1093/ije/dyn055] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Results of the Women's Health Initiative (WHI) study-which to many unexpectedly showed that hormone therapy (HT) did not decrease and may in fact have elevated risk of cardiovascular disease, while also finding expected links between HT and breast cancer-have spurred critical reflection chiefly regarding the cardiovascular results. Suggesting similar scrutiny of cancer epidemiology is warranted are new studies linking the post-WHI drop in HT use to a substantial decline in breast cancer incidence and the implications of these findings for prior explanations of the rising rates of US breast cancer incidence during the 1980s. METHODS Literature search for review and research articles on temporal trends in US breast cancer incidence during the past 25 years, starting in the mid-1980s, when extant epidemiologic evidence had already indicated that HT increased risk of breast cancer. RESULTS Among the 21 articles identified, spanning from 1987 to 2007, nine included no mention of HT as a possible factor contributing to the steep rise in breast cancer incidence in the 1980s, seven included a minor mention and only five (one published in 2003, the others in 2006 and 2007) provided any substantive discussion of this issue-but only in relation to current trends and not the 1980 rise in breast cancer incidence. CONCLUSION A critical appraisal of the epidemiologic literature highlights important gaps in explanations for breast cancer incidence trends and also how current and changing population patterns of disease distribution are ultimately what put our aetiologic explanations to the test.
Collapse
Affiliation(s)
- Nancy Krieger
- Department of Society, Human Development and Health, Harvard School of Public Health, Kresge 717, 677 Huntington Avenue, Boston, MA 02115, USA.
| |
Collapse
|
74
|
Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 16:2548-56. [PMID: 18086757 DOI: 10.1158/1055-9965.epi-07-0550] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Substantial increase in the use of menopausal hormone therapy (HT) throughout the 1990s, followed by widespread discontinuation after the 2002 publication of the Women's Health Initiative findings, has resulted in large numbers of former HT users among U.S. women. However, few studies have examined whether ovarian cancer risk varies according to recency and duration of specific HT regimens. We assessed risk of epithelial ovarian cancer among users of unopposed estrogen (ET) and combined estrogen/progestogen (EPT). In a population-based study in Washington state, 812 women with ovarian cancer diagnosed in 2002 to 2005 and 1,313 controls were interviewed in person about the use of HT and other characteristics. Women who used a single form of therapy (ET or EPT) were compared with women who never used HT using logistic regression to calculate odds ratios (OR) and 95% confidence intervals (95% CIs). Risk was increased among current or recent (within the last 3 years) users of ET with > or = 5 years of use (ORs, 95% CIs: 1.6, 1.1-2.5 and 1.8, 0.8-3.7, respectively). Little increase in risk was noted among long-term ET users who discontinued use in the more distant past (OR, 1.2; 95% CI, 0.6-2.6). No increase in risk was noted among women who used only EPT, regardless of duration. Compared with women who never used HT, current users of EPT had an OR of 1.1 (95% CI, 0.8-1.5), and risk declined with increasing time since stopping; the OR was 0.7 (95% CI, 0.4-1.0) among women who had discontinued EPT within the last 3 years and 0.5 (95% CI, 0.3-0.7) among women who stopped at an earlier point. Long-term ET may be associated with an increased ovarian cancer risk that wanes after use ceases. We did not observe an increased risk with EPT, and with increasing time after stopping, a reduction in risk became increasingly evident. The progestogen component of HT may confer a risk reduction that is masked by an opposing effect of estrogen until, among former users, estrogenic influences have diminished. These findings, if replicated, may have implications both for public health and development of chemoprevention strategies.
Collapse
Affiliation(s)
- Mary Anne Rossing
- Program in Epidemiology, Fred Hutchinson Cancer Research Center, P.O. Box 19024, Seattle, WA 98108-1024, USA.
| | | | | | | | | |
Collapse
|
75
|
Power ML, Baron J, Schulkin J. Factors Associated with Obstetrician-Gynecologists' Response to the Women's Health Initiative Trial of Combined Hormone Therapy. Med Decis Making 2008; 28:411-8. [DOI: 10.1177/0272989x07312722] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The Women's Health Initiative trial of combined estrogen and progestin (WHI E+P) ended prematurely after preliminary evidence indicated that harms exceeded benefits, with no cardiovascular benefit. There was controversy over the results and the decision to end the trial early, with many obstetrician-gynecologists expressing reservations about the evidence. The Research Department of the American College of Obstetricians and Gynecologists conducted a study regarding the WHI E+P, sending questionnaires to 2500 randomly selected Fellows; 703 Fellows returned usable surveys (28.1%). Despite almost universal awareness of the results of the WHI E+P (> 97%), almost half of the responding physicians did not find the results convincing and disagreed with the decision to stop the trial. In this further examination of the data, we identified characteristics of the respondents who were associated with either accepting or rejecting the WHI E+P. The year residency was completed, the relative importance a respondent attributed to randomized clinical trials (RCTs), concern about harms of action, and opinion of alternative therapies were significant factors. One of 5 respondents found the results convincing and agreed with the decision to end the trial (acceptors). One of 3 respondents did not find the results convincing and disagreed with the decision to end the trial (rejectors). Acceptors had completed residency more recently (1991 v. 1985, P = 0.001), rated evidence from RCTs as more important (P = 0.006), were more concerned with harms of action (22.4% v. 10.6%, P = 0.004), and were more likely to have a favorable opinion of alternative therapies to hormone therapy (64.1% v. 44.4%, P < 0.001).
Collapse
Affiliation(s)
- Michael L. Power
- Research Department, American College of Obstetricians and Gynecologists, Washington, DC,
| | - Jonathan Baron
- Department of Psychology, University of Pennsylvania, Philadelphia
| | - Jay Schulkin
- Research Department, American College of Obstetricians and Gynecologists, Washington, DC
| |
Collapse
|
76
|
Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. BMC WOMENS HEALTH 2007; 7:19. [PMID: 17945013 PMCID: PMC2233614 DOI: 10.1186/1472-6874-7-19] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/07/2007] [Accepted: 10/18/2007] [Indexed: 12/02/2022]
Abstract
Background To examine the differences in menopausal hormone therapy (MHT) use and user profiles among women in Germany before and after the communication of the Women's Health Initiative (WHI) trial and other study results concerning the risks and benefits of MHT. Methods Current MHT use was ascertained in two periodic German national health surveys conducted in 1997–1999 and 2003–2004. MHT prevalence and user profiles were assessed within each survey. The association of the survey period (2003–2004 vs. 1997–1999) with current MHT use was analyzed in weighted multivariable logistic regression (MLR) models, pooling data from both surveys. Results The overall prevalence of current MHT use decreased by 40.2% from 16.9% of the sample in 1997–1999 to 10.1% in 2003–2004. The difference in prevalence between surveys varied with age decade with the smallest decreases among women 60–69 years of age (20.3% vs. 18.5%), compared to women of younger and older age groups (40–49: 10.7% vs. 3.9%; 50–59: 36.3% vs. 21.3%; 70–79: 5.7% vs. 3.2%). Variables independently associated with higher current MHT use in both health surveys included age category (curvilinear relationship with highest use among women 50–59 years) and residence in West vs. East Germany. A higher social status, lower body mass index, and more health-conscious behaviour were significantly associated with higher current MHT use in the 1997–1999 survey, but these associations were not found in the later survey. MLR analyses confirmed a significant decline in MHT use between the 1997–1999 and 2003–2004 surveys, however, the effect was modified by social status and was not significant among lowest social-status women. Conclusion Current MHT use considerably declined among women in Germany between the pre- and post-WHI era. A convergence of current MHT use among women of higher social status with pre-existing patterns of use among lower social-status women suggests that MHT in Germany is now less likely to be used for health promotion.
Collapse
|
77
|
Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007; 9:R28. [PMID: 17477859 PMCID: PMC1929089 DOI: 10.1186/bcr1672] [Citation(s) in RCA: 248] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2007] [Revised: 03/19/2007] [Accepted: 05/03/2007] [Indexed: 11/27/2022] Open
Abstract
Introduction A recent abstract presented in a breast cancer symposium attributed the sharp decrease in female breast cancer incidence rates from 2002 to 2003 in the Surveillance, Epidemiology, and End Results (SEER) cancer registries of the United States to the reduced use of hormone replacement therapy since July 2002. However, this hypothesis does not explain the decrease that began in 1999 in the age-standardized incidence rate of invasive breast cancer in the nine oldest SEER cancer registry areas, although the trend through 2003 was not statistically significant. In this paper, we examine temporal trends in invasive and in situ female breast cancer by age, stage, tumor size, and estrogen receptor/progestin receptor (ER/PR) status in the nine oldest SEER cancer registry areas and consider the implication of these trends in relation to risk factors and screening. Methods We performed a joinpoint regression analysis to fit a series of joined straight lines to the trends in age-adjusted rates and described the resultant trends (slope) by annual percentage change (two-sided, P < 0.05). Results A plot of the age-specific rates of invasive breast cancer shows a decrease in all 5-year age groups from 45 years and above between 1999 and 2003 and sharp decreases largely confined to ER+ tumors in age groups from 50 to 69 years between 2002 and 2003. In joinpoint analyses by tumor size and stage, incidence rates decreased for small tumors (less than or equal to 2 cm) by 4.1% (95% confidence interval [CI], 0.2% to 7.8%) per year from 2000 through 2003 and for localized disease by 3.1% (95% CI, 1.2% to 5.0%) per year from 1999 through 2003. No decrease in incidence was observed for larger tumors or advanced-stage disease during the corresponding periods. Rates for in situ disease were stable from 2000 through 2003 after increasing rapidly since 1981. Conclusion Two distinct patterns are observed in breast cancer trends. The downturn in incidence rates in all age groups above 45 years suggests a period effect that is consistent with saturation in screening mammography. The sharp decrease in incidence from 2002 to 2003 that occurred in women 50 to 69 years old who predominantly, but not exclusively, had ER+ tumors may reflect the early benefit of the reduced use of hormone replacement therapy.
Collapse
Affiliation(s)
- Ahmedin Jemal
- Epidemiology and Surveillance Research, American Cancer Society, 1599 Clifton Rd. NE, Atlanta, GA 30329, USA
| | - Elizabeth Ward
- Epidemiology and Surveillance Research, American Cancer Society, 1599 Clifton Rd. NE, Atlanta, GA 30329, USA
| | - Michael J Thun
- Epidemiology and Surveillance Research, American Cancer Society, 1599 Clifton Rd. NE, Atlanta, GA 30329, USA
| |
Collapse
|
78
|
Johnson FR, Ozdemir S, Hauber B, Kauf TL. Women's Willingness to Accept Perceived Risks for Vasomotor Symptom Relief. J Womens Health (Larchmt) 2007; 16:1028-40. [PMID: 17903080 DOI: 10.1089/jwh.2006.0218] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Evidence that long-term hormone therapy (HT) may increase the risk of serious adverse events led to a sharp reduction in all HT use, including short-term use for vasomotor symptom relief. We estimated women's willingness to accept adverse event risks in exchange for vasomotor symptom relief when risks are communicated in absolute vs. relative terms. METHODS We developed a conjoint survey to elicit preferences across benefit and risk attributes of HT. The survey was administered via the Internet to 523 U.S. women aged 46-60 years. Participants evaluated pairs of hypothetical treatments and indicated preferences using a Likert-based scale. Risks were presented in absolute and relative terms. Satisfaction scores for HT risks and benefits were estimated using random-effects, ordered-probit regression. Maximum acceptable risk (MAR) was calculated as the increase in risk that reduces the satisfaction score for a given level of HT benefit to 0. RESULTS For both risk versions, the least important attribute (smallest difference in satisfaction scores) was night sweat frequency; heart attack risk was the most important (largest difference in scores). Participants were more willing to accept risks in return for symptom relief when shown absolute vs. relative risks, although differences in MAR were statistically significant only for breast cancer risk. MARs for breast cancer and heart attack exceeded reported rates in most cases. CONCLUSIONS Many women may be willing to accept risks to control vasomotor symptoms. However, describing risks in different, but technically equivalent, ways affects women's willingness to trade risks for benefits.
Collapse
Affiliation(s)
- F Reed Johnson
- Research Triangle Institute/RTI International, Research Triangle Park, North Carolina 27709-2194, USA.
| | | | | | | |
Collapse
|
79
|
Rigby AJ, Ma J, Stafford RS. Women's awareness and knowledge of hormone therapy post-Women's Health Initiative. Menopause 2007; 14:853-8. [PMID: 17429334 DOI: 10.1097/gme.0b013e3180333a33] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Findings from the Women's Health Initiative (WHI) failed to confirm previous expectations about the net benefits of menopausal hormone therapy and have resulted in reduced use of these medications. The aim of this study was to evaluate women's awareness and knowledge concerning the risks and benefits of hormone therapy. DESIGN A nationally representative survey was completed for a sample of 781 women (ages 40-60 y, mean 49 y) drawn from the Knowledge Networks Internet panel 24 months after publication of the first WHI findings, in June 2004. Responses were weighted to reflect the demographics of the US population. The main outcome measures were awareness of WHI and knowledge of its findings. An aggregate score was constructed to assess women's knowledge of the impact of hormone therapy on seven key disease outcomes. Logistic regression determined the independent predictors of (1) WHI awareness and (2) a positive aggregate knowledge score, reflecting appropriate responses about risks and benefits. RESULTS Only 29% of women were aware of the WHI results. Only 40% of women had a positive aggregate knowledge score. Aside from awareness of WHI and independent of other factors, knowledge scores were lower for African American women (odds ratio, 0.4; 95% CI: 0.2-0.6) and among women with less education (odds ratio, 0.5; 95% CI: 0.3-0.9). Knowledge was greatest for breast cancer and osteoporosis outcomes and most limited for colorectal cancer and memory loss. CONCLUSION Surveyed women had limited awareness and knowledge of the WHI results, suggesting limited diffusion. Targeting younger, less educated, and African American women is warranted.
Collapse
Affiliation(s)
- Alison J Rigby
- Division of Pediatric Endocrinology and Diabetes, and the Program on Prevention Outcomes and Practices, Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA 94305-5208, USA.
| | | | | |
Collapse
|
80
|
Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99:1152-61. [PMID: 17652280 DOI: 10.1093/jnci/djm059] [Citation(s) in RCA: 309] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Breast cancer incidence has been rising since at least 1935-1939, but recent US data reveal a statistically significant decline in breast cancer incidence in 2003 that persisted through 2004. Identifying the specific contributions of the potential causes of this long-term increase and the recent decrease in incidence has been challenging. Marked changes in rates of mammography screening and use of menopausal hormone therapy since 1980 have added further complexity. We examined the potential association between menopausal hormone therapy use and recent changes in breast cancer incidence. METHODS Using tumor registry, clinical, pathology, and pharmacy data from Kaiser Permanente Northwest, a large prepaid US health plan, we compared age-specific and age-adjusted breast cancer incidence rates (2-year moving averages) with use of screening mammography and dispensed menopausal hormone therapy prescriptions between 1980 and 2006. Temporal changes in incidence rates were assessed via joinpoint regression. RESULTS A total of 7386 incident invasive breast cancers were diagnosed in plan members from 1980 through 2006. Overall age-adjusted breast cancer incidence rates per 100,000 women rose 25% from the early 1980s (105.6) to 1992-1993 (131.7) and an additional 15% through 2000-2001 (151.3), then dropped by 18% to 2003-2004 (123.6) and edged up slightly in 2005-2006 (126.2). These patterns were largely restricted to women aged 45 years or older and to estrogen receptor-positive (ER+) breast cancers. Incidence rates of ER-negative tumors experienced neither of the rises seen for ER+ tumors but also fell precipitously from 2003 through 2006. Rates of mammography screening sharply increased from 1980 to 1993 but then leveled off, and 75%-79% of women aged 45 years or older received a mammogram at least once every 2 years from 1993 through 2006. Menopausal hormone therapy dispensings, particularly of estrogen-plus-progestin formulations, increased from 1988 to 2002 but then dropped by approximately 75% after 2002. CONCLUSIONS From 1980 through 2006, quantitative and qualitative trends in breast cancer incidence rates, particularly for ER+ tumors, parallel major changes in patterns of mammography screening and use of menopausal hormone therapy.
Collapse
MESH Headings
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Breast Neoplasms/diagnostic imaging
- Breast Neoplasms/epidemiology
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/diagnostic imaging
- Carcinoma, Ductal, Breast/epidemiology
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/diagnostic imaging
- Carcinoma, Lobular/epidemiology
- Carcinoma, Lobular/pathology
- Causality
- Databases, Factual
- Disease Progression
- Drug Utilization
- Estrogens/adverse effects
- Estrogens/therapeutic use
- Female
- Hormone Replacement Therapy/adverse effects
- Hormone Replacement Therapy/statistics & numerical data
- Hormone Replacement Therapy/trends
- Humans
- Incidence
- International Classification of Diseases
- Mammography/statistics & numerical data
- Mass Screening/statistics & numerical data
- Menopause
- Middle Aged
- Morbidity/trends
- Neoplasm Proteins/analysis
- Neoplasm Staging
- Neoplasms, Hormone-Dependent/diagnostic imaging
- Neoplasms, Hormone-Dependent/epidemiology
- Prepaid Health Plans/statistics & numerical data
- Progestins/adverse effects
- Progestins/therapeutic use
- Receptors, Estrogen/analysis
- Retrospective Studies
- United States/epidemiology
Collapse
Affiliation(s)
- Andrew G Glass
- Oncology Research, Center for Health Research, Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97227, USA.
| | | | | | | |
Collapse
|
81
|
Menon U, Burnell M, Sharma A, Gentry-Maharaj A, Fraser L, Ryan A, Parmar M, Hunter M, Jacobs I. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 2007; 14:462-7. [PMID: 17237735 DOI: 10.1097/01.gme.0000243569.70946.9d] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE There has been controversy about the results of the Women's Health Initiative and the Million Women Study and uncertainty about their impact on hormone therapy (HT) use. This study documents recent trends in HT use in postmenopausal women in the United Kingdom. DESIGN Between April 2001 and September 2005, 202,638 postmenopausal women aged 50 to 74 and with no history of bilateral oophorectomy were recruited to the United Kingdom Collaborative Trial of Ovarian Cancer Screening. The proportion of women randomized each month who were using HT was calculated. The trend in HT use was assessed with reference to the publication of the Women's Health Initiative interim results (July 2002), the Million Women Study (August 2003), and advice from the UK Committee on Safety of Medicines (December 2003). RESULTS The median number of women recruited and randomized per month was 3,955 (mean 3,744). The proportion of randomized women using HT between April 2001 and June 2002 was 29%. This was followed by a steady monthly decline, and by February to September 2005, only 10% to 11% of newly recruited women were using HT. This trend was present in all age groups. However, in current users, the average duration of HT use remained steady at 10 to 11 years. CONCLUSIONS There was a steady decline in HT use among postmenopausal women at recruitment into the United Kingdom Collaborative Trial of Ovarian Cancer Screening between April 2001 and September 2005. This is likely to reflect general trends in the UK population and is probably related to the premature closure of the large HT trials and the ensuing publicity.
Collapse
Affiliation(s)
- Usha Menon
- Department of Gynaecological Oncology, UCL Institute for Women's Health, London, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
82
|
Thompson S, Bardia A, Tan A, Barton DL, Kottschade L, Sloan JA, Christensen B, Smith D, Loprinzi CL. Levetiracetam for the treatment of hot flashes: a phase II study. Support Care Cancer 2007; 16:75-82. [PMID: 17598133 DOI: 10.1007/s00520-007-0276-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2007] [Accepted: 05/16/2007] [Indexed: 11/24/2022]
Abstract
GOALS OF WORK The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors. PATIENTS AND METHODS Women, aged 18 years or more, with a history of breast cancer or those who wished to avoid estrogen because of a perceived increased risk of breast cancer, who were experiencing bothersome hot flashes (more than or equal to 14 times per week, for more than or equal to 1 month before study entry), were included. During the baseline week, general demographic characteristics, hot flash information, and quality of life data were obtained. At the beginning of week 2, patients were started on levetiracetam for a total of 4 weeks. Information about hot flashes, quality of life, and toxicity were collected during these 4 weeks and compared with the baseline week. MAIN RESULTS After treatment with levetiracetam for 4 weeks (N = 19), mean hot flash scores (frequency times mean severity) were reduced by 57%, and mean hot flash frequencies were reduced by 53%, compared to the baseline week; both these reductions were greater than what would be expected with a placebo (20-25% reduction). There were significant improvements in abnormal sweating (p = 0.004), hot flash distress (p = 0.0002), and satisfaction of hot flash control (p = 0.0001), when comparing data from the fourth week of treatment to the baseline week. Twenty-nine percent of the subjects did not complete the study because of treatment-related adverse events, with the most frequently reported side effects being somnolence, fatigue, and dizziness, usually with mild to moderate intensity. CONCLUSION The results of this pilot trial suggest that levetiracetam might be an effective therapy for the treatment of hot flashes. Further data are needed to test this hypothesis, evaluating the efficacy and toxicity of this agent.
Collapse
Affiliation(s)
- Susan Thompson
- Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
83
|
Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. Cancer Causes Control 2007; 18:723-33. [PMID: 17549595 DOI: 10.1007/s10552-007-9015-7] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2006] [Accepted: 04/19/2007] [Indexed: 12/28/2022]
Abstract
OBJECTIVE This work assessed associations between colorectal cancer risk and postmenopausal/contraceptive hormones; subgroup analyses included women with a clinically defined family history of cancer. METHODS A population based case-control study of incident colorectal cancer was conducted among women aged 20-74 years in Ontario and Newfoundland & Labrador, Canada. Incident cases (n = 1,404) were selected from provincial cancer registries and controls (n = 1,203) were identified through property records, and other means, between January 1997 and April 2006. Family history of cancer, exogenous hormone-use, and other risk factors were collected via self-administered questionnaires. Multivariate unconditional logistic regression analyses were used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CIs). RESULTS Decreased risks of colorectal cancer were observed with ever-users of: hormonal contraceptives (OR: 0.77; CI: 0.65-0.91), estrogen-only postmenopausal hormones (OR: 0.60; CI: 0.47-0.75), and estrogen-progestin postmenopausal hormones (OR: 0.70; CI: 0.52-0.95). Risk estimates were similar between women with and without a strong familial history of cancer. Age at initiation of hormonal contraceptives was associated with colorectal cancer risk; women who initiated use at younger ages (age <22 years: OR: 0.60; CI: 0.47-0.77) experienced a greater reduced risk of disease than women who initiated use at later ages (age 30+: OR: 0.92; CI: 0.68-1.24; p (trend): 0.0026). CONCLUSIONS These results indicate that exogenous hormone-use is linked with reduced risk of colorectal cancer among women with a strong familial risk of cancer, consistent with observations on population samples of sporadic colorectal cancer cases. A potential age-effect for use of hormonal contraceptives warrants further attention.
Collapse
Affiliation(s)
- Peter T Campbell
- Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
| | | | | | | | | |
Collapse
|
84
|
Pettee KK, Kriska AM, Conroy MB, Johnson BD, Orchard TJ, Goodpaster BH, Averbach FM, Kuller LH. Discontinuing hormone replacement therapy: attenuating the effect on CVD risk with lifestyle changes. Am J Prev Med 2007; 32:483-9. [PMID: 17533063 PMCID: PMC2040271 DOI: 10.1016/j.amepre.2007.02.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2006] [Revised: 01/12/2007] [Accepted: 02/07/2007] [Indexed: 11/19/2022]
Abstract
BACKGROUND Concern about the potential risks associated with hormone replacement therapy (HRT) has left post-menopausal women and healthcare providers searching for safe and effective means for cardiovascular disease (CVD) risk factor reduction. METHODS The Woman On the Move through Activity and Nutrition study is a 5-year clinical trial (2002-2006) designed to test whether a lifestyle intervention will reduce measures of subclinical CVD. Participants were randomized at baseline to a health education or lifestyle change group. The impact of lifestyle intervention on CVD risk factors was examined in 240 women who were initially on HRT at baseline and either continued (n = 110) or discontinued (n = 130) by 18 months. RESULTS The lifestyle-change group significantly decreased weight, body mass index, waist circumference (all p<0.0001), total cholesterol (p=0.02), and LDL cholesterol (LDL-C) (p= 0.01), improved fat intake (p<0.0001), and increased leisure physical activity (p=0.005) when compared with the health education group. HRT discontinuation resulted in increased total cholesterol (p=0.04) and LDL-C (p=0.009). CVD risk factor changes were further explored by the HRT group, stratified by randomized group assignment. Within the health education arm, HRT discontinuers averaged over a 22-mg/dL increase in total cholesterol and LDL-C, while HRT continuers averaged less than 4 mg/dL (p=0.004 and 0.002, respectively). No such differences were noted in the lifestyle-change group (p=0.78 and 0.90, respectively). CONCLUSIONS Lifestyle modification was effective for CVD risk factor reduction in post-menopausal women. HRT discontinuation resulted in increased total cholesterol and LDL-C, which were successfully attenuated by a lifestyle intervention incorporating weight loss, physical activity, and dietary modification.
Collapse
Affiliation(s)
- Kelley K Pettee
- Department of Exercise and Wellness, Arizona State University, 7350 E. Unity Drive, Mesa, AZ 85212, USA.
| | | | | | | | | | | | | | | |
Collapse
|
85
|
Rolnick SJ, Jackson J, Kopher R, Defor TA. Provider management of menopause after the findings of the Women's Health Initiative. Menopause 2007; 14:441-9. [PMID: 17318028 DOI: 10.1097/gme.0b013e31802cc7bc] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE A survey was conducted to determine current provider behaviors and concerns related to menopause management. DESIGN All gynecology, internal medicine, and family medicine providers (both physicians and nurse practitioners) within a large Midwestern integrated health system were surveyed about current approaches to menopause management, frequency and reasons for hormone therapy (HT) use, approaches to HT discontinuation, treatments for symptom control, bone mineral density testing, and concerns related to menopause management. Descriptive statistics and chi-square tests were performed to examine frequencies and differences based on gender, specialty, and years in practice. RESULTS Overall the response rate was 58% with providers from owned clinics, with female providers being the most likely to respond (P < 0.001). Changes in menopause management included using lower dose hormones (74%), encouraging use for shorter time periods (73%), and using different modes of delivery (21%). Most providers (89%) initiate HT use in symptomatic patients, and only 12% initiate use to prevent symptoms. Patients were most likely to discuss HT with gynecologists (78% gynecologists vs 64% family medicine providers and 48% internal medicine providers, P = 0.015). Nearly two thirds of providers (64%) claimed to order bone mineral density testing frequently. Providers' concerns related to information on symptom management, alternative and over-the-counter medications, the risk/benefits of medications, patients' sexual concerns, and maintaining bone health. CONCLUSIONS We found that providers were responsive to current literature, shifting the agents and dosages they prescribe. Still they are faced with women reporting symptoms that interfere with their ability to function optimally and must continue to help women maintain healthy bones.
Collapse
Affiliation(s)
- Sharon J Rolnick
- HealthPartners Research Foundation, Minneapolis, MN 55440-1524, USA.
| | | | | | | |
Collapse
|
86
|
Pettee KK, Kriska AM, Johnson BD, Conroy MB, Mackey RH, Orchard TJ, Kuller LH. The relationship between physical activity and lipoprotein subclasses in postmenopausal women: the influence of hormone therapy. Menopause 2007; 14:115-22. [PMID: 17023874 DOI: 10.1097/01.gme.0000229573.29258.d5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVE This study's objective was to determine if the association between physical activity and lipids and lipoprotein subclasses in postmenopausal women varies by hormone therapy (HT) use. DESIGN The cross-sectional relationship between physical activity and lipid and lipoprotein subclass relationship was examined before group randomization in 485 postmenopausal (mean age 56.9 [2.9] y) white and African American women from the Woman On the Move through Activity and Nutrition study. This study is a randomized clinical trial designed to test whether a lifestyle intervention will reduce subclinical cardiovascular disease measures. RESULTS Hormone therapy users (n = 286) were significantly (P < 0.05) younger, less likely to be African American, reported higher levels of physical activity, large very low-density lipoprotein particles (VLDL-P), and medium high-density lipoprotein particles (HDL-P), had a larger mean HDL-P size, and lower levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, small HDL-P, and small VLDL-P than nonusers (n = 196). Physical activity was significantly associated with favorable lipoprotein and lipid levels, regardless of HT use. Some relationships were found to vary significantly by HT use. In nonusers, mean HDL-P and LDL particles (LDL-P) size was significantly larger (P = 0.01 and 0.05, respectively) and total and small LDL-P were significantly lower (both P = 0.02) as activity increased. These relationship were not found in HT users. CONCLUSIONS Physical activity was significantly related to some lipoprotein subclasses regardless of HT; however, several key lipoprotein subclasses were associated with higher levels of activity only among non-HT users.
Collapse
Affiliation(s)
- Kelley K Pettee
- Department of Epidemiology, Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
| | | | | | | | | | | | | |
Collapse
|
87
|
Aberegg SK, Arkes H, Terry PB. Failure to adopt beneficial therapies caused by bias in medical evidence evaluation. Med Decis Making 2007; 26:575-82. [PMID: 17099195 DOI: 10.1177/0272989x06295362] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Although it is known that many evidence-based therapies are underutilized, the causes of the research-practice gap are not well understood. The authors sought to determine if there is a bias in the evaluation of new evidence that leads to low rates of adoption of beneficial therapies compared to abandonment of harmful ones. METHODS Two case vignettes describing hypothetical clinical trials were administered to 2 independent samples of pulmonary and critical care practitioners. Each vignette was presented in 2 different ways; in one version, the results of the hypothetical trial showed that a treatment was harmful, and in the other version, the same treatment was shown to be beneficial. Prospective respondents from each sample were randomized to receive 1 version of each vignette (intersubject design). The main outcome was respondent's willingness to apply the results of the hypothetical trial to patient care. RESULTS There were 174 participants for trial 1 and 138 participants for trial 2 (enrollment rates of 44.2% and 41.8%, respectively). For trial 1, respondents were 2.3 times less likely to change clinical practice based on results indicating benefit as opposed to harm (33.3% v. 76.5%; P < 0.0001). Similarly, for trial 2, respondents were 2.57 times less likely to change practice when trial results showed that early use was beneficial as opposed to showing that early use was harmful (37.1% v. 95.3%; P < 0.0001). CONCLUSIONS When evaluating clinical trials, physicians demonstrate less willingness to adopt beneficial therapies than to abandon harmful ones. This difference may contribute to the research-practice gap.
Collapse
Affiliation(s)
- Scott K Aberegg
- Johns Hopkins Medical Institutions,Department of Medicine, Division of Pulmonary and Critical CareMedicine, Baltimore, MD, USA.
| | | | | |
Collapse
|
88
|
Dorval M, Vallée MH, Plante M, Chiquette J, Gaudet M, Simard J. Effect of the Women's Health Initiative Study Publication on Hormone Replacement Therapy Use among Women Who Have Undergone BRCA1/2 Testing. Cancer Epidemiol Biomarkers Prev 2007; 16:157-60. [PMID: 17220345 DOI: 10.1158/1055-9965.epi-06-0340] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Since the publication, in July 2002, of the Women's Health Initiative (WHI) study, use of hormone replacement therapy (HRT) has decreased substantially in the general population. However, little is known about the effect of WHI study results on HRT use among women at high risk of breast cancer. The purpose of this study is to compare HRT use, prepublication versus postpublication of the WHI study, among women tested for BRCA1/2 mutations. METHODS Participants were >35 years of age and had received their result of genetic testing (delivered within the interdisciplinary research program Interdisciplinary Health Research International Team on Breast Cancer Susceptibility), no later than February 28, 2005. HRT use was reported in self-administered questionnaires, 1 year after result disclosure. Women returning their questionnaire before July 17, 2002 were classified as pre-WHI, whereas those returning it after October 15, 2002 comprised the post-WHI group. RESULTS Four hundred fifty-seven women (199 and 258 in the pre-WIH and post-WHI groups, respectively) were included in this analysis. Globally, there was no difference in HRT use between prepublication and postpublication of the WHI study (8% and 11%, respectively; prevalence ratio, 0.74; 95% confidence interval, 0.43-1.28). However, noncarriers of the familial mutation were less likely to use HRT after publication of the WHI study results (9%) than before (21%; P = 0.03). CONCLUSIONS Overall, HRT use among women tested for BRCA1/2 mutations is relatively low and apparently uninfluenced by the WHI study findings. However, the HRT use reduction among noncarriers is similar to that of women in the general population and consistent with the Canadian Cancer Society's recent HRT use recommendations.
Collapse
Affiliation(s)
- Michel Dorval
- Faculté de pharmacie, Université Laval, Quebec, Canada.
| | | | | | | | | | | |
Collapse
|
89
|
Power ML, Schulkin J, Rossouw JE. Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists. Menopause 2007; 14:20-8. [PMID: 17019376 DOI: 10.1097/01.gme.0000229571.44505.cb] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The objective of this study was to examine the opinions and prescribing practices of obstetrician-gynecologists regarding hormone therapy (HT) and the results from the Women's Health Initiative. DESIGN Surveys were sent to 2,500 randomly selected American College of Obstetrics and Gynecology fellows during December 2004 to March 2005; their responses are compared with those from a survey conducted in November to December 2003. RESULTS Respondents remained skeptical of the combined HT results (49.1% did not find the results convincing). Compared with the 2003 survey, men were more skeptical (58.8% did not consider the findings convincing in 2004 vs 53.4% in 2003, P = 0.045), and women were somewhat less skeptical (39.5% did not consider the findings convincing in 2004 vs 45.3% in 2003, P = 0.056). There was less skepticism about the estrogen-only trial, although 4 of 10 did not find the results convincing. Men were more skeptical than women; a majority of men disagreed with the decisions to stop the trials. Physicians who completed their residency more recently were more likely to accept the trial results. Respondents reported a reduction in HT prescription practice relative to the year 2000, but 62.7% reported they did not expect their prescribing practices to change further in the near future. The proportion of respondents who considered alternative therapies to HT as viable treatment options increased between 2003 and 2004 (37.1% vs 28.1%, P < 0.001). There was strong support for the use of HT for vasomotor symptoms, vaginal dryness, and osteoporosis, but most physicians did not consider HT useful for cardiovascular disease or dementia. CONCLUSIONS Many obstetrician-gynecologists continue to express skepticism about the results and conduct of the Women's Health Initiative trials. The survey could not determine the reasons for skepticism.
Collapse
Affiliation(s)
- Michael L Power
- Department of Research, American College of Obstetricians and Gynecologists, Washington, DC 20024, USA.
| | | | | |
Collapse
|
90
|
Lindh-Astrand L, Brynhildsen J, Hoffmann M, Liffner S, Hammar M. Attitudes towards the menopause and hormone therapy over the turn of the century. Maturitas 2007; 56:12-20. [PMID: 16797891 DOI: 10.1016/j.maturitas.2006.05.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2006] [Revised: 05/08/2006] [Accepted: 05/09/2006] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To assess attitudes and beliefs about the menopausal transition in a population of peri- and postmenopausal women, and if these attitudes differed before and after publication of studies on risks and benefits with hormone therapy (HT). MATERIALS AND METHODS In 1999 and 2003 all women aged 53 and 54 years in the community of Linköping, Sweden, were sent a questionnaire about use of HT, menopausal status and attitudes regarding menopause and HT. RESULTS Most women regarded menopause as a natural process characterized by both hormonal deficiency and aging and these views did not differ between 1999 and 2003. A majority of women thought that significant climacteric symptoms were a good reason to use HT, but not that women without symptoms should use HT. The fraction of women who supported HT use was, however, significantly lower in 2003 than in 1999. Most women agreed that menopause leads to increased freedom and that it is a relief not to have to think about contraception and pregnancies. CONCLUSIONS Most Swedish women had a mainly biological view on menopause but nevertheless they thought that only women with climacteric symptoms should use HT. Women's attitudes towards HT have changed after recent reports on risks from long-term use of HT whereas the attitudes towards the menopausal transition were stable. Other factors than attitudes towards menopause affect women's actual use of HT. Probably women's and health care provider's apprehension of the risk-benefit balance of HT use is one such factor.
Collapse
Affiliation(s)
- Lotta Lindh-Astrand
- Division of Obstetrics and Gynecology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, University Hospital, S-581 85 Linköping, Sweden.
| | | | | | | | | |
Collapse
|
91
|
Aiello EJ, Buist DSM, White E. Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States). Cancer Causes Control 2006; 17:1227-35. [PMID: 17111253 DOI: 10.1007/s10552-006-0073-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2005] [Accepted: 05/04/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To evaluate whether the association between hormone therapy (HT) and breast density differs by levels of breast cancer risk factors. METHODS We evaluated 80,867 screening mammograms from 39,296 postmenopausal women from Washington State. We estimated odds ratios and 95% confidence intervals for dense breasts (Breast Imaging Reporting and Data System categories 3 "heterogeneously dense" and 4 "extremely dense") compared to fatty breasts (categories 1 "almost entirely fat" and 2 "scattered fibroglandular") among HT users compared to never users. We separately examined former HT use and current HT use by type (estrogen plus progestin therapy (EPT) and estrogen-only therapy (ET)). We stratified the associations by age, BMI, race, family history, and reproductive and menopausal factors. RESULTS Current EPT users had a 98% (1.87-2.09) greater odds of having dense breasts and current ET users had a 71% (1.56-1.87) greater odds compared to never users. Current HT users were more likely to have dense breasts if they were older, had more children, or younger at first birth compared to never users; these associations were stronger among EPT users than ET users. CONCLUSIONS HT, particularly EPT, may reduce protective effects of older age, parity, and younger age at first birth on mammographic density.
Collapse
Affiliation(s)
- Erin J Aiello
- Group Health Center for Health Studies, Suite 1600, Seattle, WA 98101, USA.
| | | | | |
Collapse
|
92
|
Wegienka G, Havstad S, Kelsey JL. Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination. J Womens Health (Larchmt) 2006; 15:369-78. [PMID: 16724885 DOI: 10.1089/jwh.2006.15.369] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND In July 2002, the Women's Health Initiative (WHI) published results that led to early termination of the randomized controlled trial of estrogen plus progestin in postmenopausal women with an intact uterus. Subsequently, the trial of estrogen only also was terminated early, and the results were published in April 2004. The present study examines the impact of both sets of results on menopausal hormone therapy (MHT) prescription patterns, as well as the characteristics of women who did and did not change their MHT behavior after publication of results. METHODS We examined the number of MHT prescriptions filled in the months before and after each set of results was published, using claims data from 24,446 women aged 50-79 years continuously enrolled in a health maintenance organization (HMO) at Henry Ford Health System from January 2000 through December 2004. RESULTS After July 2002, a statistically significant (p < 0.05) drop occurred in the rate of MHT prescriptions filled; 29% of the women stopped MHT for at least 4 months, but 24% of these women resumed use by December 2004. Successful stoppers tended to be older. Twenty-one percent of users in April 2004 stopped in May 2004 for at least 4 months; 25% of these had restarted by December. Women continued to initiate MHT after July 2002, but at lower rates in 2003 and 2004 (73% and 77% decreases, respectively, compared with 2001). The types of MHT prescriptions obtained by new users changed after 2001: fewer initiated MHT with oral Premarin (Wyeth, St. David's, PA) and Prempro or Premphase (Wyeth-Ayerst, Philadelphia, PA), and more initiated MHT with Premarin and Estrace (Warner Chilcott, Rockaway, NJ) creams. CONCLUSIONS Regardless of the goals of the WHI study, the publication of results on estrogen plus progestin in July 2002 impacted overall rates of MHT use, as did, to a lesser extent, the estrogen only results published in May 2004. Although women continued to initiate MHT after the results were published, they were less likely to use the formulations from the WHI and instead used formulations for which there is less information about effectiveness and long-term health consequences.
Collapse
Affiliation(s)
- Ganesa Wegienka
- Department of Biostatistics and Research Epidemiology, Henry Ford Health System, Detroit, Michigan, USA
| | | | | |
Collapse
|
93
|
Barron TI, Bennett K, Feely J. Impact of high dose statin trials on hospital prescribers. Eur J Clin Pharmacol 2006; 63:65-72. [PMID: 17115149 DOI: 10.1007/s00228-006-0208-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2006] [Accepted: 09/04/2006] [Indexed: 10/23/2022]
Abstract
BACKGROUND The PROVE-IT and REVERSAL studies established that an intensive 80 mg/day dose of atorvastatin was superior to pravastatin 40 mg/day for the secondary prevention of coronary heart disease (CHD) following acute coronary syndromes and in limiting the progression of coronary atherosclerosis. We have evaluated the impact of the results from these studies on statin prescribing by hospital doctors in the 2 years following their publication. METHODS AND RESULTS Using a nationwide database, 18,894 patients receiving a total of 23,750 hospital discharge prescriptions for atorvastatin were identified between September 2002 and December 2005. From this cohort, patients newly commenced on, switched to, or dose titrated on atorvastatin by a hospital prescriber were identified. The mean daily atorvastatin dose on discharge was calculated for each month and the results were analysed using a segmented regression analysis. There was a significant and sustained increase in the mean atorvastatin dose used by hospital prescribers. This resulted in an increase of 12 mg, (95% CI 10.6, 13.4) in the mean dose prescribed by December 2005. This was attributable largely to a 16.4% (95% CI 13.5, 19.3), 17.2% (95% CI 14.0, 20.5) and 8.8% (95% CI 7.4, 10.2) increase in the prescribing of the 20 mg, 40 mg and 80 mg/day dosages, respectively. CONCLUSION The PROVE-IT and REVERSAL studies have had a significant impact on hospital prescribers' choice of atorvastatin dose. It is likely that this has been the result of both the publication and effective promotion of results from these trials.
Collapse
Affiliation(s)
- Thomas I Barron
- Department of Pharmacology and Therapeutics, Trinity College Dublin, St Jame's Hospital, Dublin 8, Ireland.
| | | | | |
Collapse
|
94
|
Shrader SP, Ragucci KR. Life After the Women's Health Initiative: Evaluation of Postmenopausal Symptoms and Use of Alternative Therapies After Discontinuation of Hormone Therapy. Pharmacotherapy 2006; 26:1403-9. [PMID: 16999650 DOI: 10.1592/phco.26.10.1403] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
STUDY OBJECTIVE To determine the number of women who have menopausal symptoms after discontinuing hormone therapy, to determine how many of these women subsequently require nonhormonal alternatives to manage their symptoms, and to assess the effectiveness of those therapies. DESIGN One-year retrospective study. SETTING Department of Family Medicine outpatient clinic at a university medical center. PATIENTS From 378 postmenopausal women who discontinued hormone therapy between August 1, 2002, and August 31, 2003, we randomly selected 78 using electronic medical records to provide a sample with a 95% confidence interval and a 10% margin of error. MEASUREMENTS AND MAIN RESULTS Reasons why the women discontinued therapy and any nonhormonal alternative therapies that they may have used to manage subsequent menopausal symptoms were recorded. The primary investigator contacted the 78 women to complete a telephone survey. In most women, at least one menopausal symptom recurred. Vasomotor symptoms (hot flashes) were most common and occurred in 41 (53%) women. In addition, 59 (76%) women reported using nonhormonal alternative therapies, and 40 (68%) of this group deemed the alternatives helpful. CONCLUSION We strongly believe that health care providers, including pharmacists, must continue to communicate with and educate women regarding treatment options for menopausal symptoms. Clinical pharmacists are ideally suited to contribute to ongoing research in this area.
Collapse
Affiliation(s)
- Sarah P Shrader
- Department of Pharmacy and Clinical Sciences/Family Medicine, South Carolina College of Pharmacy, Medical University of South Carolina Campus, Charleston, South Carolina 29425, USA.
| | | |
Collapse
|
95
|
Bültzingslöwen KV, Pfeifer M, Kröner-Herwig B. Ein kognitiv-verhaltenstherapeutisches Gruppentraining für Frauen mit Wechseljahresbeschwerden – Ergebnisse einer kontrollierten Gruppenstudie. VERHALTENSTHERAPIE 2006. [DOI: 10.1159/000094830] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
96
|
Kalpakjian CZ, Quint EH, Tate DG, Roller S, Toussaint LL. Menopause characteristics of women with physical disabilities from poliomyelitis. Maturitas 2006; 56:161-72. [PMID: 16930875 DOI: 10.1016/j.maturitas.2006.07.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2005] [Revised: 07/11/2006] [Accepted: 07/21/2006] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To describe menopause characteristics of women with physical disabilities from poliomyelitis. METHODS Nine hundred and nine women with a history of poliomyelitis completed a survey on health, physical functioning, emotional well being and menopause. RESULTS The majority of the sample was postmenopausal having had a natural menopause around the average age of 50.3 years; 34.7% of the sample had had hysterectomies. Thirty-nine percent were using some form of hormone replacement therapy (HRT). Menopause symptoms were clustered into psychological, somatic-sensory, somatic-sleep and vasomotor factors. Among never and past HRT users, there were significant differences in menopause factor severity by menopause status. Somatic/sleep symptoms were lowest in never users; past users had significantly higher vasomotor symptoms; desire for sexual activity and painful intercourse did not vary by HRT use. Compared to population estimates, post-polio women had similar rates of hysterectomies overall, but among some age cohorts they had significantly lower rates, contrary to expectations. However, they used HRT at significantly higher rates than expected. CONCLUSIONS This study suggests that basic menopause characteristics of women with polio are generally similar to those of their non-disabled peers. There were few substantial differences in severity of menopause symptoms by HRT use, which is critical in light of the dearth of studies examining its risk-benefit ratio among women with physical disabilities. Until such studies provide some evidence of the specific risks or benefits to women with physical disability, each woman should carefully weigh the known risks and benefits with her physician.
Collapse
Affiliation(s)
- Claire Z Kalpakjian
- Department of Physical Medicine and Rehabilitation, University of Michigan Health System, 300 N. Ingalls, NI 2A09, Ann Arbor, MI 48109-0491, USA.
| | | | | | | | | |
Collapse
|
97
|
Abstract
OBJECTIVE In 2002, the combination estrogen-progestin hormone therapy (HT) treatment arm of the Women's Health Initiative was terminated early because cardiovascular and cancer risks were identified, while the estrogen-only therapy (ET) arm of this trial continued. We investigated hormone therapy prescription practice changes between 2001 and 2003 to explore the effects of the clinical trial results. METHODS Data were obtained from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey for the years 2001 through 2003. These nationally representative surveys sample medical encounters in nonfederally employed physician's offices and outpatient departments of nonfederal short-stay and general hospitals. The proportion and rate of visits with ET and HT prescriptions were calculated. Logistic regression was used to estimate change over time accounting for patient and provider characteristics. RESULTS Between 2001 and 2003, the number of visits with menopausal hormone prescriptions fell from 26.5 million to 16.9 million. Almost three-quarters of hormone visits were for ET prescriptions. The decrease in the rate of visits was slightly larger for HT prescription visits (44%) than ET prescription visits (35%). The rate of decline was highest among women 50 years of age and over. After controlling for covariates, there was no significant difference in the decline by hormone type. CONCLUSION These nationally representative data indicate substantial declines in menopausal hormone prescriptions coinciding with clinical trial results on HT. These declines occurred among all types of therapy and patient characteristics. LEVEL OF EVIDENCE II-3.
Collapse
Affiliation(s)
- Esther Hing
- Division of Health Care Statistics, and Office of Analysis and Epidemiology, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland 20782, USA.
| | | |
Collapse
|
98
|
Lee E, Wutoh AK, Xue Z, Hillman JJ, Zuckerman IH. Osteoporosis management in a Medicaid population after the Women's Health Initiative study. J Womens Health (Larchmt) 2006; 15:155-61. [PMID: 16536679 DOI: 10.1089/jwh.2006.15.155] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Publication of the Women's Health Initiative (WHI) study has changed our understanding on the effects of hormone replacement therapy. This study was designed to evaluate patterns of antiosteoporosis medication (AOM) use in a Medicaid population before and after the release of the WHI study results. METHODS A descriptive time series analysis was conducted among women 50 years of age and older who were enrolled in the Pennsylvania Medicaid program from December 1, 2001, through December 31, 2002. All AOMs were identified, including estrogens, bisphosphonates, selective estrogen receptor modulators (SERMs), and calcitonin. The monthly prevalence of each AOM and drug class was estimated. Comparisons between pre-WHI (December 1, 2001-July 30, 2002) and post-WHI (August 1, 2002-December 31, 2002) study periods were made for overall AOM use by AOM drug class as well as by recipient characteristics. RESULTS The overall prevalence of AOM did not change between pre-WHI and post-WHI study publication. However, there were significant changes in the prevalence of certain AOM drug classes. Estrogen use decreased significantly after the WHI study release for all age and racial groups. The prevalence for bisphosphonates and SERM increased significantly in the post-WHI period. CONCLUSIONS The WHI study influenced patterns of use of all types of AOM, decreasing estrogen and increasing nonestrogen use among postmenopausal women in a Medicaid program. These results suggest that the WHI study affected patterns of use of bone protective pharmacotherapy, with a shift in bone protection therapy use from estrogen to nonestrogen AOMs.
Collapse
Affiliation(s)
- Euni Lee
- Center for Minority Health Services Research, Department of Clinical and Administrative Pharmacy Sciences, School of Pharmacy, Howard University, Washington, DC, USA
| | | | | | | | | |
Collapse
|
99
|
Bardia A, Thompson S, Atherton PJ, Barton DL, Sloan JA, Kottschade LA, Christensen B, Collins M, Loprinzi CL. Pilot Evaluation of Aprepitant for the Treatment of Hot Flashes. ACTA ACUST UNITED AC 2006; 3:240-6. [DOI: 10.3816/sct.2006.n.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
100
|
Palmlund I. Loyalties in clinical research on drugs: The case of hormone replacement therapy. Soc Sci Med 2006; 63:540-51. [PMID: 16490295 DOI: 10.1016/j.socscimed.2005.06.057] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2004] [Accepted: 06/14/2005] [Indexed: 11/24/2022]
Abstract
In this study, physicians' loyalties toward patients and pharmaceutical companies in clinical drug research are explored, using Bourdieu's conceptual tools. The utilization of estrogen supplements in so-called hormone replacement therapy (HRT) for healthy menopausal and postmenopausal women is used as a case. For over 60 years a multitude of reports in medical journals have praised the benefits of HRT, even though some studies indicated hazards. Clinical studies and promotional campaigns resulted in prescriptions of HRT for millions of women. A large randomized controlled clinical trial known as the Women's Health Initiative (WHI) in 2002 demonstrated that many of the claims of benefits of HRT had been misguiding; the risks of cancer and heart disease had been proven higher than most purported benefits. I draw on Bourdieu's theories to emphasize that a more distinct demarcation line between those who dispose their economic capital in the interests of producing and promoting products for profit, and those who exchange their cultural capital for economic benefits, is needed to ensure trust in physicians' loyalty to patients is not eroded.
Collapse
Affiliation(s)
- Ingar Palmlund
- The Wellcome Trust Centre for the History of Medicine, University College London, UK.
| |
Collapse
|